Alzheimer’s disease is the most common form of dementia, affecting millions worldwide. Notably, women bear a disproportionate burden, with approximately two-thirds of individuals diagnosed with Alzheimer’s disease being female1, 2. While this discrepancy was once attributed primarily to women’s longer life expectancy, emerging research suggests a more complex interplay of genetic, hormonal, menopause, biological, and societal factors contributing to this increased susceptibility.
Hormonal Influence: Estrogen’s Role in Brain Health
One of the most significant biological distinctions between men and women is hormonal differences, particularly estrogen. Estrogen has been shown to have neuroprotective effects, aiding in synaptic plasticity, reducing inflammation, and promoting brain cell survival. However, after menopause, women experience a sharp decline in estrogen levels, which may contribute to increased vulnerability to Alzheimer’s disease3.
Protective Effects of Estrogen
Estrogen has neuroprotective properties, helping to maintain brain tissue integrity and cognitive function4. It promotes healthy activity in the brain, protects against toxic insults, and may reduce deposition and enhance clearance of β-amyloid and tau, two key proteins that build up in Alzheimer’s disease pathology5, 6. The “critical window hypothesis” suggests that estrogen therapy taken around the time of menopause may lower dementia risk in old age7. Research suggests that estrogen replacement therapy (ERT) could potentially mitigate some of these risks if administered at the right time. One study showed that women who took estrogen in mid-life had a decreased risk of developing dementia compared to those who never took estrogen8. However, results have been mixed, and the timing of hormone therapy appears to be crucial, with potential risks associated with late initiation of treatment.
More on Science Rabbit
The Link Between Shingles and Stroke Explained
Prof. Andrew Bubak (PhD, MS) – The varicella zoster virus (VZV), primarily known for causing chickenpox and shingles, can reactivate and significantly increase stroke…
Why menopause matters
While the exact timing of ERT treatment may vary from woman to woman, there may be a key common denominator—menopause. Estrogen levels change dramatically leading up to menopause. As estrogen levels decrease, many changes occur in the brain and body. Estrogen plays a significant role in helping our primary energy source (a molecule called glucose) reach the brain9. This may lead to our brain cells becoming unhealthy over time. These changes may be helpful to biomarkers in assessing the risk of women who are susceptible over time.
Immune System Differences and Amyloid Plaque Accumulation
Another compelling biological factor is the immune system’s role in Alzheimer’s progression. Women generally have stronger immune responses than men, which can be beneficial for fighting infections10. However, this heightened immune activity may also lead to increased accumulation of amyloid plaques—the protein that is a hallmark of Alzheimer’s disease11. Over time, excessive plaque buildup contributes to neurodegeneration and cognitive impairment. While there is evidence the immune system plays a critical role in the risk and development of Alzheimer’s disease, much more research is needed to understand the differences between men and women.
Gender-Specific Life Experiences and Alzheimer’s Risk
Beyond biology, social and experiential factors also play a role in Alzheimer’s risk. Studies suggest that pregnancy complications, hormonal fluctuations across a woman’s lifetime, and even gender-based differences in education and employment history may influence cognitive resilience later in life12. For example, lower levels of formal education—historically more common in older women—have been linked to a higher risk of Alzheimer’s disease. Cognitive stimulation through lifelong learning and career engagement has been shown to promote brain health and delay cognitive decline13, 14.
Healthcare Inequities and Diagnosis Delays
Women also face disparities in healthcare access and diagnosis, which can impact the progression and treatment of Alzheimer’s. Medical gaslighting—where women’s symptoms are dismissed or downplayed—may lead to delays in diagnosis and intervention15. Additionally, because women often serve as primary caregivers for others, they may prioritize the health of family members over their own, delaying their own medical care.
Research indicates that women are diagnosed with Alzheimer’s disease at later stages compared to men, potentially due to gender biases in healthcare. Earlier diagnosis and intervention are crucial in managing Alzheimer’s, highlighting the need for more gender-sensitive medical practices.
Moving Toward Solutions
Understanding why women are more susceptible to Alzheimer’s is critical for developing targeted prevention and treatment strategies. Here are some key areas of focus for future research and public health initiatives:
- Personalized Medicine: Given the differences in how Alzheimer’s manifests in men and women, more gender-specific research and treatment approaches are needed.
- Early Intervention: Improving screening tools for women, particularly postmenopausal women, can help detect early signs of cognitive decline before significant damage occurs.
- Hormonal Research: More studies are needed to determine the optimal timing and safety of estrogen-based therapies for brain health.
- Healthcare Equity: Addressing biases in healthcare and ensuring that women’s cognitive concerns are taken seriously can lead to earlier diagnosis and better outcomes.
- Lifelong Brain Health Strategies: Encouraging women to engage in continuous learning, maintain social connections, and manage cardiovascular health can all contribute to reducing Alzheimer’s disease risk.
Conclusion
Women’s increased susceptibility to Alzheimer’s is a complex issue shaped by longevity, genetics, hormonal shifts, immune responses, and societal factors. While research is still uncovering the full picture, one thing is clear: addressing these gender-specific risks and ensuring equitable healthcare access are essential steps toward better prevention, diagnosis, and treatment of Alzheimer’s disease. By understanding and acknowledging these differences, we can move closer to a future where Alzheimer’s risk is reduced for everyone, regardless of gender.
About the author:
Dr. Christy Niemeyer (PhD) is a Professor of Neurology that researches neurophysiological mechanisms in the context of neurodegenerative and neurocognitive disorders. Her laboratory currently studies how sex differences and hormones influence Alzheimer’s disease progression.
References
- Thies W, Bleiler L. 2013 Alzheimer’s disease facts and figures. Alzheimer’s & Dementia. 2013;9(2):208-45. doi: 10.1016/j.jalz.2013.02.003.
- Beam CR, Kaneshiro C, Jang JY, Reynolds CA, Pedersen NL, Gatz M. Differences Between Women and Men in Incidence Rates of Dementia and Alzheimer’s Disease. Journal of Alzheimer’s Disease. 2018;64(4):1077-83. doi: 10.3233/jad-180141.
- Wood Alexander M, Honer WG, Saloner R, Galea LAM, Bennett DA, Rabin JS, Casaletto KB. The interplay between age at menopause and synaptic integrity on Alzheimer’s disease risk in women. Science Advances. 2025;11(10). doi: 10.1126/sciadv.adt0757.
- Behl C, Manthey D. Journal of Neurocytology. 2000;29(5/6):351-8. doi: 10.1023/a:1007109222673.
- Buckley RF, Mormino EC, Rabin JS, Hohman TJ, Landau S, Hanseeuw BJ, Jacobs HIL, Papp KV, Amariglio RE, Properzi MJ, Schultz AP, Kirn D, Scott MR, Hedden T, Farrell M, Price J, Chhatwal J, Rentz DM, Villemagne VL, Johnson KA, Sperling RA. Sex Differences in the Association of Global Amyloid and Regional Tau Deposition Measured by Positron Emission Tomography in Clinically Normal Older Adults. JAMA Neurology. 2019;76(5):542. doi: 10.1001/jamaneurol.2018.4693.
- Hara Y, Waters EM, McEwen BS, Morrison JH. Estrogen Effects on Cognitive and Synaptic Health Over the Lifecourse. Physiological Reviews. 2015;95(3):785-807. doi: 10.1152/physrev.00036.2014.
- Marchant I, Stojanova J, Acevedo L, Olivero P. Estrogen rapid effects: a window of opportunity for the aging brain? Neural Regen Res. 2022;17(8):1629. doi: 10.4103/1673-5374.332121.
- Whitmer RA, Quesenberry CP, Zhou J, Yaffe K. Timing of hormone therapy and dementia: The critical window theory revisited. Annals of Neurology. 2011;69(1):163-9. doi: 10.1002/ana.22239.
- Rettberg JR, Yao J, Brinton RD. Estrogen: A master regulator of bioenergetic systems in the brain and body. Frontiers in Neuroendocrinology. 2014;35(1):8-30. doi: 10.1016/j.yfrne.2013.08.001.
- Thaker AA, McConnell BV, Rogers DM, Carlson NE, Coughlan C, Jensen AM, Lopez-Paniagua D, Holden SK, Pressman PS, Pelak VS, Filley CM, Potter H, Solano DA, Heffernan KS, Bettcher BM. Astrogliosis, neuritic microstructure, and sex effects: GFAP is an indicator of neuritic orientation in women. Brain, Behavior, and Immunity. 2023;113:124-35. doi: 10.1016/j.bbi.2023.06.026.
- Buckley RF. Sex differences in Alzheimer’s disease risk: are immune responses the key? Brain. 2022;145(10):3341-2. doi: 10.1093/brain/awac316.
- Sharp ES, Gatz M. Relationship Between Education and Dementia. Alzheimer Disease & Associated Disorders. 2011;25(4):289-304. doi: 10.1097/wad.0b013e318211c83c.
- Flexman R. Lifelong Learning. Delaware Journal of Public Health. 2021;7(4):124-7. doi: 10.32481/djph.2021.09.015.
- Woods B, Rai HK, Elliott E, Aguirre E, Orrell M, Spector A. Cognitive stimulation to improve cognitive functioning in people with dementia. Cochrane Database of Systematic Reviews. 2023;2023(1). doi: 10.1002/14651858.cd005562.pub3.
- Durbhakula S, Fortin AH. Turning Down the Flame on Medical Gaslighting. Journal of General Internal Medicine. 2023;38(15):3426-7. doi: 10.1007/s11606-023-08302-4.
Leave a Reply